{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:43:00Z","timestamp":1769240580241,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2020-19-15"],"award-info":[{"award-number":["320.6750.2020-19-15"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non\u2013small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad339","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T20:46:51Z","timestamp":1704919611000},"page":"543-545","source":"Crossref","is-referenced-by-count":2,"title":["Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non\u2013Small Cell Lung Cancer: A Case Report"],"prefix":"10.1093","volume":"29","author":[{"given":"Huaiyu","family":"Wang","sequence":"first","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiwen","family":"Fan","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[{"name":"Anesthesiology Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wu","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingna","family":"Zhu","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Liu","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"You","sequence":"additional","affiliation":[{"name":"The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd , Nanjing, Jiangsu Province , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Department, Air Force Medical Center, PLA , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2024060305560131400_CIT0001","first-page":"702","article-title":"Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report","volume-title":"BMC Cancer","author":"Liu","year":"2019"},{"key":"2024060305560131400_CIT0002","first-page":"e258","article-title":"Resolving resistance to osimertinib therapy with afatinib in an NSCLC patient with EGFR L718Q mutation","volume-title":"Clin Lung Cancer","author":"Yang","year":"2020"},{"key":"2024060305560131400_CIT0003","first-page":"760097","article-title":"Case Report: dacomitinib overcomes osimertinib resistance in NSCLC patient harboring L718Q mutation: a case report","volume-title":"Front Oncol","author":"Shen","year":"2021"},{"key":"2024060305560131400_CIT0004","first-page":"8","article-title":"Oligometastases","volume-title":"J Clin Oncol","author":"Hellman","year":"1995"},{"key":"2024060305560131400_CIT0005","first-page":"2242","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume-title":"Cancer","author":"Wong","year":"2016"},{"key":"2024060305560131400_CIT0006","first-page":"1672","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume-title":"Lancet Oncol","author":"Gomez","year":"2016"},{"key":"2024060305560131400_CIT0007","first-page":"1558","article-title":"Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume-title":"J Clin Oncol","author":"Gomez","year":"2019"},{"key":"2024060305560131400_CIT0008","first-page":"157","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume-title":"Radiother Oncol","author":"Lievens","year":"2020"},{"key":"2024060305560131400_CIT0009","first-page":"e18","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume-title":"Lancet Oncol","author":"Guckenberger","year":"2020"},{"key":"2024060305560131400_CIT0010","first-page":"1383","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume-title":"J Thorac Oncol","author":"Xu","year":"2018"},{"key":"2024060305560131400_CIT0011","first-page":"346","article-title":"Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors","volume-title":"J Thorac Oncol","author":"Yu","year":"2013"},{"key":"2024060305560131400_CIT0012","first-page":"192","article-title":"Approach for oligometastasis in non-small cell lung cancer","volume-title":"Gen Thorac Cardiovasc Surg","author":"Suzuki","year":"2016"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/6\/543\/58038401\/oyad339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/6\/543\/58038401\/oyad339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:40:31Z","timestamp":1717425631000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/6\/543\/7514804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad339","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,1,10]]}}}